Amgen Q1 top line off 1%; earnings up 9%; cash flow up 25%; earnings guidance raised; shares down 3% after hours on revenue miss

|About: Amgen Inc. (AMGN)|By:, SA News Editor

Amgen (NASDAQ:AMGN) Q1 results ($M): Total Revenues: 5,464 (-1.1%); Product Sales: 5,199 (-0.8%).

Net Income: 2,071 (+9.0%); Non-GAAP Net Income: 2,333 (+5.9%); EPS: 2.79 (+11.6%); Non-GAAP EPS: 3.15 (+8.6%); CF Ops: 2,385 (+24.5%).

Key Product Sales: Neulasta: 1,210 (+2.3%); Enbrel: 1,181 (-14.7%); Aranesp: 511 (-3.9%); Prolia: 425 (+20.7%); Sensipar/Mimpara: 421 (+14.7%); XGEVA: 402 (+6.3%); EPOGEN: 270 (-10.0%); KYPROLIS: 190 (+23.4%): Repatha: 49 (-15.5% sequentially).

2017 Guidance: Total Revenues: $22.3B - 23.1B (unch); EPS: $10.64 - 11.32 from $10.45 - 11.31; Non-GAAP EPS: $12.00 - 12.60 from $11.80 - 12.60.

Shares are down 3% after hours on robust volume. Revenues missed consensus by $140M.